The Lancet Digital Health:人工智能算法识别前列腺癌**度高达98%

2020-07-30 转化医学网 转化医学网

前列腺癌是发生于前列腺的上皮恶性肿瘤,是男性泌尿生殖系统最常见的恶性肿瘤之一。前列腺癌在疾病早期阶段,多数患者无明显症状,一旦前列腺癌开始快速生长或扩散到前列腺外,病情就非常严重了。因此,前列腺癌的前

2020年7月27日,匹兹堡大学医学中心(UPMC)和匹兹堡大学的研究人员在《柳叶刀数字健康》(The Lancet Digital Health)上发表了一项新研究,该研究表明,迄今为止,使用人工智能(AI)程序识别和表征前列腺癌是准确性最高的

UPMC Shadyside的首席病理学家和病理学副主席、匹兹堡大学的生物医学信息学教授、该研究的资深作者Rajiv Dhir表示,人类善于识别异常,但他们有自己的偏见或过去的经验。机器不是这样的。机器有一个标准化护理的要素。

为了训练人工智能识别前列腺癌,Dhir和他的同事们提供了从病人活检中提取的100多万份染色组织切片的图像。每幅图像都由专家病理学家进行标记,以教人工智能如何区分健康和异常组织。然后,该算法在一组单独的1600张幻灯片上进行了测试,这些幻灯片取自UPMC的100名疑似前列腺癌患者。

在检测过程中,人工智能在检测前列腺癌方面显示出98%的敏感性和97%的特异性,这显着高于之前报道的使用组织切片的算法。

此外,这是第一个超越癌症检测的算法,报告了对肿瘤分级、大小和周围神经的侵犯的高性能。这些都是重要的临床特征,需要作为病理报告的一部分。AI还标记了六张病理学专家没有注意到的幻灯片。

Galen前列腺第二阅读系统的算法和临床部署概述

但Dhir解释说,这并不一定意味着机器优于人类。例如,在评估这些病例的过程中,病理学家可以简单地从病人的其他样本中看到足够的恶性证据来推荐治疗。不过,对于经验不足的病理学家来说,该算法可以作为一种故障保险,来捕捉可能被遗漏的病例。

在该论文中,研究人员报告了一种用于评估数字化前列腺CNB切片、基于医疗级人工智能的算法的发展,以及该人工智能工具在常规临床实践中的成功应用。基于一个大的,盲的,外部验证数据集,研究人员展示了该算法的高精度,以识别和量化前列腺癌,区分低级别和高级别的肿瘤,并检测神经周围浸润。

这是第一个基于人工智能的算法的报告,它超越了前列腺癌在组织病理学图像中的癌症检测和分级,也是临床上首次在常规病理学实践中使用人工智能算法的实例之一。

总之,匹兹堡大学医学中心的研究人员报告了基于人工智能的算法的发展、外部临床验证和常规实践中的部署,该算法用于检测、分级和评估数字化前列腺CNBs的其他临床相关肿瘤特征。这些数据表明,这种基于人工智能的算法可以作为一种工具,用于自动筛查前列腺CNBs的初级诊断,评估登记的病例以达到质量控制的目的,以及标准化报告以改进患者管理。在其他实验室和相关临床效用的研究报告目前也正在进行中。

原始出处:

Liron Pantanowitz,et al. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study. The Lancet Digital Health, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830762, encodeId=e14b1830e6231, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 23 16:58:52 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784333, encodeId=8e2d1e8433350, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Wed Mar 03 02:58:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861392, encodeId=669718613925c, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Jun 27 07:58:52 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621861, encodeId=b6d21621861c4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Aug 01 09:58:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805384, encodeId=f3a680538407, content=人工智能发展还是很很迅速啊,期待应用的前景!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Jul 31 15:01:35 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033906, encodeId=201210339069b, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040796, encodeId=085d1040e9644, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2021-04-23 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830762, encodeId=e14b1830e6231, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 23 16:58:52 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784333, encodeId=8e2d1e8433350, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Wed Mar 03 02:58:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861392, encodeId=669718613925c, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Jun 27 07:58:52 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621861, encodeId=b6d21621861c4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Aug 01 09:58:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805384, encodeId=f3a680538407, content=人工智能发展还是很很迅速啊,期待应用的前景!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Jul 31 15:01:35 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033906, encodeId=201210339069b, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040796, encodeId=085d1040e9644, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2021-03-03 venlin
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830762, encodeId=e14b1830e6231, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 23 16:58:52 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784333, encodeId=8e2d1e8433350, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Wed Mar 03 02:58:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861392, encodeId=669718613925c, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Jun 27 07:58:52 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621861, encodeId=b6d21621861c4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Aug 01 09:58:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805384, encodeId=f3a680538407, content=人工智能发展还是很很迅速啊,期待应用的前景!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Jul 31 15:01:35 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033906, encodeId=201210339069b, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040796, encodeId=085d1040e9644, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2021-06-27 shizhenshan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830762, encodeId=e14b1830e6231, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 23 16:58:52 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784333, encodeId=8e2d1e8433350, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Wed Mar 03 02:58:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861392, encodeId=669718613925c, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Jun 27 07:58:52 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621861, encodeId=b6d21621861c4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Aug 01 09:58:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805384, encodeId=f3a680538407, content=人工智能发展还是很很迅速啊,期待应用的前景!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Jul 31 15:01:35 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033906, encodeId=201210339069b, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040796, encodeId=085d1040e9644, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1830762, encodeId=e14b1830e6231, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 23 16:58:52 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784333, encodeId=8e2d1e8433350, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Wed Mar 03 02:58:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861392, encodeId=669718613925c, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Jun 27 07:58:52 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621861, encodeId=b6d21621861c4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Aug 01 09:58:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805384, encodeId=f3a680538407, content=人工智能发展还是很很迅速啊,期待应用的前景!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Jul 31 15:01:35 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033906, encodeId=201210339069b, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040796, encodeId=085d1040e9644, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-07-31 ms3000000449926787

    人工智能发展还是很很迅速啊,期待应用的前景!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1830762, encodeId=e14b1830e6231, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 23 16:58:52 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784333, encodeId=8e2d1e8433350, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Wed Mar 03 02:58:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861392, encodeId=669718613925c, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Jun 27 07:58:52 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621861, encodeId=b6d21621861c4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Aug 01 09:58:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805384, encodeId=f3a680538407, content=人工智能发展还是很很迅速啊,期待应用的前景!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Jul 31 15:01:35 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033906, encodeId=201210339069b, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040796, encodeId=085d1040e9644, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-07-30 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1830762, encodeId=e14b1830e6231, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 23 16:58:52 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784333, encodeId=8e2d1e8433350, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Wed Mar 03 02:58:52 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861392, encodeId=669718613925c, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Jun 27 07:58:52 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621861, encodeId=b6d21621861c4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Aug 01 09:58:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805384, encodeId=f3a680538407, content=人工智能发展还是很很迅速啊,期待应用的前景!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Jul 31 15:01:35 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033906, encodeId=201210339069b, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040796, encodeId=085d1040e9644, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 30 21:58:52 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-07-30 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Brit J Cancer:血浆肿瘤DNA是转移去势抵抗性前列腺癌治疗响应的早期指标

治疗时的血浆肿瘤DNA(ptDNA)水平与各种癌症的响应有关。然而,ptDNA在前列腺癌监控中的作用仍旧未有探索。最近,有研究人员鉴定了治疗期间ptDNA的动态,并评估了ptDNA对转移去势抵抗性前列

Cell Death & Disease:WFDC2能够抑制前列腺癌的转移

WFDC2是一个小分子分泌蛋白,在卵巢癌中已有广泛的研究。之前的研究已经证实WFDC2能够促进卵巢癌的增殖和转移,并且可作为诊断生物标记。然而,WFDC2在前列腺癌中的特定功能还未报道。

Brit J Cancer:前列腺癌积极监控,手术或者放疗的成本-效益分析比较

目前,局部前列腺癌治疗方法的成本-效益相关证据仍旧有限。最近,有研究人员在一个UK NHS前瞻性前列腺癌检测和治疗(ProtecT)随机对照试验中评估了积极监控,手术和放疗的成本-效果情况。该试验的随

Prostate Cancer P D:5α-还原酶抑制剂治疗患者中PI-RADS评分v.2预测恶性肿瘤情况分析

最近,有研究人员调查了PI-RADS评分是否在进行5α-还原酶抑制剂(dutasteride)治疗患者中是一种有效的检测前列腺癌的工具,并鉴定了总血清PSA和PSA密度阈值。

Mol Cell :雄激素受体结构对前列腺癌的启示

雄激素受体是受雄激素激活的转录因子,在雄性的生长发育中起到了关键作用,在雄性和雌性的数个组织中存在,控制着雄性性征的发育与生长,调节着雄性和雌性的头发生长和性冲动,是前列腺癌的发生和发展的关键启动蛋白

Oncogene:MYC下调MEIS1介导前列腺癌的发展

在大多数男性中,局部前列腺癌发展非常缓慢。雄激素受体(AR)和MYC转录因子是前列腺癌致瘤中最为明确的驱使因子。腔内前列腺癌细胞中MYC的上调与AR的终端分化作用相反。然而,MYC上调的作用具有多效性